Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Xianzhong Bai"'
Autor:
Jianhui Ma, Yan Song, Jianzhong Shou, Yuxian Bai, Hanzhong Li, Xiaodong Xie, Hong Luo, Xiubao Ren, Jiyan Liu, Dingwei Ye, Xianzhong Bai, Cheng Fu, Shukui Qin, Jinwan Wang, Ai-Ping Zhou
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. An
Externí odkaz:
https://doaj.org/article/b7cf31287a7b4934860ef32fed34d45d
Autor:
Xiuwen Wang, Jianhui Ma, Hong Luo, Jinwan Wang, Shukui Qin, Hanzhong Li, Ji-Yan Liu, Jun Li, Cheng Fu, Benkang Shi, Yuxian Bai, Ai Ping Zhou, Dingwei Ye, Xiu Bao Ren, Xianzhong Bai, Yan Song, Ying Cheng
Publikováno v:
The Oncologist. 24:e702-e708
Background Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first-line treatment for patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de4481151e9a6f54c3942809c84b639
https://doi.org/10.1634/theoncologist.2018-0839
https://doi.org/10.1634/theoncologist.2018-0839
Autor:
Yan Song, Hanzhong Li, Hong Luo, Jianhui Ma, Ji-Yan Liu, Yuxian Bai, Dingwei Ye, Shukui Qin, Jinwan Wang, Aiping Zhou, Jianzhong Shou, Xiaodong Xie, Xianzhong Bai, Xiubao Ren, Cheng Fu
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Introduction: Sequential therapy with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) is effective in some patients with metastatic renal cell carcinoma (mRCC) progressed from or were intolerant to a prior TKIs. An
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8e481c33f3ab9992fa87e0bf8b83115
https://doi.org/10.3389/fonc.2020.00664
https://doi.org/10.3389/fonc.2020.00664
Publikováno v:
Therapeutics and Clinical Risk Management
Hao-Yuan Lu,1,* Wei Wei,2,* Qi-Wei Chen,1,* Qing-Gui Meng,1 Gao-Hua Hu,1 Xian-Lin Yi,1,3 Xian-Zhong Bai1 1Department of Urology, Tumor Hospital of Guangxi Medical University and Guangxi Cancer Research Institute, Nanning 530021, China; 2Department of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c173c8ab6e12915ec5f45ecc7685ddfd
http://europepmc.org/articles/PMC5848664
http://europepmc.org/articles/PMC5848664
Autor:
Xinqing Ye, Haoyuan Lu, Qinggui Meng, Yun Ma, Jinan Guo, Xianlin Yi, Xianzhong Bai, Jiwen Cheng, Rui Lin, Hongxiang Zhang
Publikováno v:
Journal of cellular biochemistry. 120(8)
Estrogen-related receptor α (ERRα) belongs to the superfamily of nuclear orphan receptors. However, the role of ERRα in bladder cancer remains unknown. This study examined the expression of ERRα in bladder cancer tissues and explored the molecula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f12c17e003bd8209dac7ed1d80e7a2a1
https://pubmed.ncbi.nlm.nih.gov/30977157
https://pubmed.ncbi.nlm.nih.gov/30977157
Publikováno v:
Molecular Medicine Reports. 6:955-960
Mesenchymal stem cells (MSCs) are generally used in tissue engineering, regenerative medicine and therapy for immune disorder disease. MSCs are also employed as drug carriers for tumor therapy due to their ability to migrate to tumor tissue. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e51d6e520cb453e40786a1a7c671b1
https://doi.org/10.3892/mmr.2012.1019
https://doi.org/10.3892/mmr.2012.1019
Autor:
Haoyuan Lu, Keji Xie, Shao-Jun Jiang, Jiweng Cheng, Yang Shen, Yong Tang, Qinggui Meng, Rubiao Ou, Xianlin Yi, Xianzhong Bai, Yuexian Wu, Fengxue Wu
Publikováno v:
Oncology Letters
Cystitis glandularis (CG) has been hypothesized as a potential precursor of adenocarcinoma, although this remains controversial. The present study reports data accumulated from 166 cases of cystitis glandularis with follow-up periods ranging between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892fac4403a9966eb079ac8cdf655eed
http://europepmc.org/articles/PMC4156188
http://europepmc.org/articles/PMC4156188
Autor:
Aiping Zhou, Shukui Qin, Xianzhong Bai, Hangzhong Li, Cheng Fu, Xiubao Ren, Yan Song, Yuxian Bai, Hong Luo, Ji-Yan Liu, Xiaodong Xie, Dingwei Ye, Jinwan Wang, Jianhui Ma
Publikováno v:
Journal of Clinical Oncology. 34:4565-4565
4565Background: Anlotinib is a potent oral, small molecular TKI with a favorable safety profile in phase I clinical trial which mainly targets VEGFR1/2/3, FGFR2. This multicenter randomized phase I...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a28f61ca7c1ce54035a8276fb0ae61e3
https://doi.org/10.1200/jco.2016.34.15_suppl.4565
https://doi.org/10.1200/jco.2016.34.15_suppl.4565
Autor:
Hangzhong Li, Hong Luo, Dingwei Ye, Aiping Zhou, Xiubao Ren, Xianzhong Bai, Shukui Qin, Ji-Yan Liu, Yan Song, Xiaodong Xie, Yuxian Bai, Jinwan Wang, Cheng Fu, Jianhui Ma
Publikováno v:
Journal of Clinical Oncology. 34:e16082-e16082
e16082Background: Fibroblast growth factor (FGF) signaling regulates tumor growth and vascularization and partly mediates antiangiogenic escape from VEGFR inhibitors. Sequential TKI treatment has b...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1396e34f1c45556eb3def2fe73afba9
https://doi.org/10.1200/jco.2016.34.15_suppl.e16082
https://doi.org/10.1200/jco.2016.34.15_suppl.e16082
Autor:
XIANLIN YI, HAOYUAN LU, YUEXIAN WU, YANG SHEN, QINGGUI MENG, JIWENG CHENG, YONG TANG, FENGXUE WU, RUBIAO OU, SHAOJUN JIANG, XIANZHONG BAI, KEJI XIE
Publikováno v:
Oncology Letters; 2014, Vol. 8 Issue 4, p1662-1664, 3p